digital currency us dollar, searches

Shengyi Technology: The total sales volume of the company's rigid copper clad laminate ranks second in the world. Shengyi Technology said at the collective exchange meeting of investors that according to the statistics and ranking of the global rigid copper clad laminate in 2023 by Prismark of the United States, the total sales volume of the company's rigid copper clad laminate ranks second in the world, with a global market share of 14%. Regarding the growth trend of AI server, the company said that the upgrade iteration of hardware equipment related to AI server is fast, and the product form is quite different from that of previous wired products. The company can quickly respond to customer requirements and provide solutions. It is expected that AI applications will gradually develop from large model training to application in the future, and it is expected to achieve good growth.Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.Jordan sold his Chicago mansion for $9.5 million, with a price reduction of 67%. According to Beiqing Sports, Michael Jordan, a famous former American professional basketball player, sold his manor mansion on the outskirts of Chicago for $9.5 million. In 2012, the public price of this mansion was $29 million. After 12 years of listing, the price was reduced by 67% and it was finally sold.

To ensure that patients across the country will use the drugs selected in April next year, the tenth batch of drugs organized by the state will be opened for centralized procurement, and the tenth batch of drugs organized by the state will be selected in Shanghai yesterday, and 62 drugs will be purchased successfully. Covering hypertension, diabetes, tumors, cardiovascular and cerebrovascular diseases, infections, mental diseases and other fields. In the next step, the National Medical Insurance Bureau will guide local and selected enterprises to do a good job in the implementation of the selected results to ensure that patients across the country can use the selected products in this centralized collection in April 2025. (CCTV News)It is reported that Canada is considering imposing export taxes on commodities such as uranium and oil to counter Trump's tariff threat. Canada is studying the imposition of export taxes on major commodities exported to the United States, including uranium, oil and potash, in the case that Trump fulfills the comprehensive tariff threat. Officials familiar with the internal discussions of Canadian Prime Minister Trudeau's government said that the export tax would be Canada's last resort. According to people familiar with the matter, retaliatory tariffs on goods made in the United States and export controls on some Canadian products are more likely to come first. However, these officials said that if Trump decides to launch a full-scale trade war, the commodity export tax is a practical option, which will push up the costs of American consumers, farmers and enterprises. They said that the Trudeau government may also propose to expand its export control power in the latest report on the country's financial and economic situation scheduled to be released on Monday. It is reported that Canada is currently the largest external oil supplier in the United States. Some refineries rely on cheaper Canadian heavy crude oil, and there are few other options. The impact of rising costs is particularly severe in the Midwest of the United States, where nearly half of the crude oil used by fuel producers to produce gasoline and diesel comes from Canada.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.

Zhu Xiaohong, the former party secretary of Guizhou Aerospace Hospital, was decided to be arrested. According to the news of "Guizhou Procuratorate" WeChat WeChat official account, the case of Zhu Xiaohong, the former party secretary of Guizhou Aerospace Hospital (director level), was investigated by Zunyi City Supervision Committee and transferred to the procuratorate for review and prosecution. Under the jurisdiction designated by Zunyi Municipal People's Procuratorate, Fenggang County People's Procuratorate will review and prosecute. A few days ago, the Fenggang County People's Procuratorate made an arrest decision on Zhu Xiaohong on suspicion of accepting bribes. The case is being further processed.Comments on Hong Kong stocks: Hang Seng Index fell by 2.09%, Hang Seng Technology Index fell by 2.63%, Hong Kong stocks closed, Hang Seng Index fell by 2.09% and Hang Seng Technology Index fell by 2.63%. Domestic insurance stocks and domestic housing stocks were among the top losers, with Sunac China falling more than 8%, and Xpeng Motors, China Pacific Insurance and Zijin Mining falling more than 5%.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.